Filing Flows › Arcutis Biotherapeutics (ARQT) › Recalls, complaints & regulation
Arcutis Biotherapeutics (ARQT): clinical trials
Arcutis Biotherapeutics (ARQT) beyond its filings: 2 active clinical trials.
Arcutis Biotherapeutics' latest quarter
Arcutis Biotherapeutics, Q3 2026: revenue $144M (+45% year over year), operating margin 6.6%, net earnings $8.8M, operating cash flow $18.9M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Arcutis Biotherapeutics have?
2 active studies on ClinicalTrials.gov, 1 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.